Unleashing the Power of Spectral Shift Technology

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection mass spectrometry (ASMS) can be limited by sensitivity or sample demand. Spectral Shift is a fluorescence-based biophysical technique used to quantify the strength of molecular interactions. It offers a powerful alternative to traditional biochemical assays and ASMS, directly quantifying protein–ligand interactions in a high-throughput format.

At SLAS 2026, WuXi Biology and Testing scientists presented a poster describing a Spectral Shift–based direct binding assay implemented using NanoTemper Technologies' Spectral Shift technology, enabling detection of protein–ligand interactions with high sensitivity and low material consumption. The authors showcase results that highlight Spectral Shift as a versatile HTS approach for accelerating early discovery decisions.